Literature DB >> 19355942

Calcium-sensing receptor (CaSR) in human brain's pathophysiology: roles in late-onset Alzheimer's disease (LOAD).

Anna Chiarini1, Ilaria Dal Pra, Maddalena Marconi, Balu Chakravarthy, James F Whitfield, Ubaldo Armato.   

Abstract

Although the calcium-sensing receptor (CaSR) is expressed by all types of nerve cells in widespread areas of the human central nervous system (CNS), so far its roles in brain pathophysiology remain largely unknown. Here, we review the available evidence concerning the stages of development of sporadic late-onset Alzheimer's disease (LOAD) and the roles therein played by CaSR signaling. As the brain ages, its ability to dispose of dangerous synapse-targeting soluble amyloid beta-(1-42) (sAbeta42) oligomers released from normal neuronal activity declines. As their levels slowly rise, these oligomers increasingly target and eliminate synapses and prevent synapse formation, thereby eroding the foundations of memory formation and cognitive functions. In this initial stage, neurons, even though synaptically impaired, remain alive. Concurrently, sAbeta42 oligomers by binding to CaSR on human astrocytes induce via mitogen activated protein kinase (MAPK) activity the release of huge amounts nitric oxide (NO), which by itself and after conversion to peroxynitrite (ONOO(-)) damages neighboring neurons. When the sAbeta42 oligomers increasingly aggregate into fibrillar plaques, they attract and activate microglial macrophages that, while trying to clear the plaques, produce via Abeta-activated CaSR signaling several proinflammatory cytokines and reactive oxygen species (ROS). Notably, the microglial cytokines, like sAbeta42 oligomers, induce human astrocytes to make large amounts of NO and hence ONOO(-) via CaSR signal-dependent MAPK activity. The microglial cytokines-activated astrocytes might also produce their own sAbeta42, which would combine with neuron- and microglia-released sAbeta42 to increase the fibrillar burden and promote the further production of reactive oxygen species (ROS), NO/ONOO(-), and proinflammatory cytokines to efficiently kill both normal and functionally impaired (undead) neurons. But, on a somewhat positive note, we speculate that the astrocytes' CaSR-stimulated MAPK activities might also induce vascular endothelial growth factor (VEGF) expression and production. This might in turn enhance neuronal stem cells neurogenesis at least in the subgranular zone (SGZ) of the hippocampal dentate gyrus.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19355942     DOI: 10.2174/138920109787847501

Source DB:  PubMed          Journal:  Curr Pharm Biotechnol        ISSN: 1389-2010            Impact factor:   2.837


  9 in total

1.  Transcriptomic Profiling Reveals Discrete Poststroke Dementia Neuronal and Gliovascular Signatures.

Authors:  Rajesh N Kalaria; Stephen B Wharton; Rachel Waller; Yoshiki Hase; Julie E Simpson; Paul R Heath; Matthew Wyles
Journal:  Transl Stroke Res       Date:  2022-05-31       Impact factor: 6.800

2.  Identifying the Mechanisms and Molecular Targets of Yizhiqingxin Formula on Alzheimer's Disease: Coupling Network Pharmacology with GEO Database.

Authors:  Tingting Zhang; Linlin Pan; Yu Cao; Nanyang Liu; Wei Wei; Hao Li
Journal:  Pharmgenomics Pers Med       Date:  2020-10-15

Review 3.  Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer's disease.

Authors:  Tiantian Guo; Denghong Zhang; Yuzhe Zeng; Timothy Y Huang; Huaxi Xu; Yingjun Zhao
Journal:  Mol Neurodegener       Date:  2020-07-16       Impact factor: 14.195

Review 4.  Calcium regulation of neural rhythms, memory and Alzheimer's disease.

Authors:  Michael J Berridge
Journal:  J Physiol       Date:  2013-06-10       Impact factor: 5.182

Review 5.  Signaling pathways regulating neuron-glia interaction and their implications in Alzheimer's disease.

Authors:  Hong Lian; Hui Zheng
Journal:  J Neurochem       Date:  2015-11-30       Impact factor: 5.372

6.  Calcium-Sensing Receptors of Human Astrocyte-Neuron Teams: Amyloid-β-Driven Mediators and Therapeutic Targets of Alzheimer's Disease.

Authors:  I Dal Prà; A Chiarini; R Pacchiana; E Gardenal; B Chakravarthy; J F Whitfield; U Armato
Journal:  Curr Neuropharmacol       Date:  2014-07       Impact factor: 7.363

7.  CaSR Antagonist (Calcilytic) NPS 2143 Hinders the Release of Neuroinflammatory IL-6, Soluble ICAM-1, RANTES, and MCP-2 from Aβ-Exposed Human Cortical Astrocytes.

Authors:  Anna Chiarini; Ubaldo Armato; Peng Hu; Ilaria Dal Prà
Journal:  Cells       Date:  2020-06-02       Impact factor: 6.600

Review 8.  EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease.

Authors:  Vladimir Khavinson; Natalia Linkova; Ekaterina Kozhevnikova; Svetlana Trofimova
Journal:  Molecules       Date:  2020-12-31       Impact factor: 4.411

Review 9.  Role of methylglyoxal in Alzheimer's disease.

Authors:  Cristina Angeloni; Laura Zambonin; Silvana Hrelia
Journal:  Biomed Res Int       Date:  2014-03-09       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.